Skip to main content

Enzymatica gets full market coverage through wholesale agreement with Tamro

Press Release   •   Dec 02, 2013 13:22 GMT

The biotech company Enzymatica has signed an agreement with the pharmacy wholesaler, Tamro, for the distribution and sale of, ColdZyme® Mouth Spray – against common cold, on the Swedish market. The agreement means that consumers will have even more opportunities to buy the product which will be on sale at pharmacy chains such as Cura and Lloyds. Enzymatica already has agreements with the majority of Sweden’s pharmacy chains.

”This is Enzymatica’s first agreement with any of the major wholesalers which supply both prescription and over-the-counter pharmaceutical products, as well as other health and medical care products to pharmacies. Through the agreement, we can supply ColdZyme Mouth Spray to just about any pharmacy in Sweden,” says Michael Edelborg Christensen, CEO of Enzymatica.

Enzymatica already has agreements with Apoteket AB, Kronans Droghandel, Apotek Hjärtat, Medstop, Vårdapoteket and individual pharmacies in Apoteksgruppen, as well as most on-line pharmacies. The agreement with Tamro adds an additional 130 pharmacies through Cura and Lloyds. Their sales represent around 15 percent of the market in the cold treatments category. This means that ColdZyme Mouth Spray has full market coverage, now available at around 1150 of Sweden’s 1280 pharmacies.

ColdZyme® Mouth Spray is a CE-marked medical device product which is intended to reduce the risk of catching a cold or shorten the duration of the illness, if used in the early stages when symptoms are first noticed. It acts by forming a protective barrier in the mouth and throat. Enzymatica has carried out a clinical pilot study involving 46 people at Skåne University Hospital in Lund. The results were reported in September, and showed that, compared with placebo, ColdZyme Mouth Spray reduced both the quantity of virus present and the duration of the common cold in people infected with the cold virus. The product was registered with the Swedish Medical Products Agency as a class I medical device product in August 2012. ColdZyme Mouth Spray was successfully launched broadly from September 2013 and has established a clear position as one of the 10 most selling brands in the OTC common cold category in Sweden.

For more information, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ), +46 (0)768-14 41 66, michael.christensen@enzymatica.se


About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »


Comments (0)

Add comment

Comment